The agreement covered a proposed 10MW AI-enabled facility with local government development approval. It granted X2M binding exclusivity over the site and its power capacity for 60 days.
Decidr AI Industries Ltd describes itself as an agentic AI enablement group. It owns Decidr.ai, developer of the Decidr Agentic Operating System known as DecidrOS, the Sugarwork knowledge-capture platform and the Edible Beauty retail business. The company's FY26 audited annual report, released on 30 …
SenSen Networks (ASX:SNS) supplies its SenDISA platform and related hardware and implementation services. The technology combines video analytics with data from other sensing systems to identify events and support operational decisions. Its applications include kerbside and parking enforcement, traffic monitoring, public compliance functions and …
Cogstate Limited (ASX:CGS) provides computerised cognitive assessments, clinical trial endpoint measurement and data-quality services for neuroscience drug development and healthcare. Its FY26 results documented higher recognised revenue, an expanded clinical trial portfolio and investment plans for artificial intelligence-enabled operations. In the 20 October 2026 …
Artrya’s software processes cardiac CT images to help clinicians assess coronary anatomy and characteristics of plaque in arteries. Its products are designed to support, rather than replace, clinician interpretation. The company describes the platform as AI-based diagnostic-support software on its official website.
FortifAI Limited is an ASX-listed technology company focused on artificial intelligence and advanced computing through its subsidiary NOL8. NOL8’s AI Data Plane gives organisations visibility into how data moves through their AI systems.
The company's February 2026 roadmap set out three stages: a Demonstration Engine, a Customer Benchmarking Engine targeted for July 2026 and a revenue-ready Commercial Engine by the end of calendar year 2026. Version 1.0, the Customer Benchmarking Engine, launched on 29 June 2026. Version …
Algorae has two related but distinct activities. The AlgoraeRx subsidiary seeks to register and distribute generic and specialty medicines in Australia and New Zealand through arrangements with manufacturers. Its target customers include hospitals, pharmacies and other institutional purchasers. Commercial delivery depends on relevant regulatory …
Enlitic Inc (ASX:ENL), a developer of artificial intelligence-enabled medical imaging data software, has expanded its Ensight product range while progressing contracts and deployments in healthcare systems. At the time of writing this article on 19 October 2026, the quoted price supplied for ENL was …
Because the business only recently changed character, historical comparisons are limited. Readers should treat the figures below as an early picture of a company still building its operating record. Goodwill of US$519.3 million from the merger dominates total assets of US$599.3 million at 30 …